The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015

Statutory Rules of Northern Ireland

2015 No. 53

Dangerous Drugs

The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015

Made

12th February 2015

Coming into operation

5th March 2015

The Department of Health, Social Services and Public Safety makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971(1) as adapted by sections 7(9), 31(4) and 38 of that Act and now vested in it(2) and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act.

Citation, commencement and interpretation

1.—(1) These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015 and come into operation on 5th March 2015.

(2) The Interpretation Act (Northern Ireland) 1954(3) shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.

Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002

2.  The Misuse of Drugs Regulations (Northern Ireland) 2002(4) are amended as follows

3.  In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) after “Tenocyclidine” insert—

“(6aR,9R-4-acetyl-N, N-diethyl-7-methyl-4, 6, 6a, 7, 8, 9-hexahydroindolo[4, 3-fg]quinoline-9-carboxamide (ALD-52”;

(b) after “4-Bromo-2,5-dimethoxy-a-methylphenethylamine” insert—

“3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)

(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)

(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”

(c) after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)”.

4.  For paragraph 1(b) of Schedule 1, substitute—

“(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent”.

5.  In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27) after “Hydromorphone” insert—

“4-Hydroxy-n-butyric acid”.

6.  In paragraph 1 of Part 1 of Schedule 4 (controlled drugs subject to the requirements of Regulations 22, 23, 26 and 27) omit “4-Hydroxy-n-butyric acid”(5).

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 12th February 2015

Dr Paddy Woods

A senior officer of the

Department of Health, Social Services and Public Safety

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations amend the Misuse of Drugs Regulations (Northern Ireland) 2002. The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.

Regulation 3 adds certain LSD related compounds and the synthetic opiate known as AH-7921 to Schedule 1 of the Regulations. Regulation 4 replaces the definition of tryptamine compounds in Schedule 1 with a wider generic definition. Regulations 5 and 6 move 4-Hydroxy-n-butyric acid (‘GHB’) from Part 1 of Schedule 4 of the Regulations to Schedule 2.

(1)

1971 c.38 as amended by s.151 of, and Schedule 17 to, the Police Reform and Social Responsibility Act 2011 c.13.

(2)

S.R.& O. (N.I.) 1973 No.504, Article 5(a) and S.I.1999/283 (N.I.1), Article 3(6).

(3)

1954 c.33 (N.I.)

(4)

S.R.2011 No.153, S.R.2010 Nos.148 and 247, S.R.2009 No.390, S.R.2007 No.348, S.R.2005 No.360 and S.R.2003 No.314.

(5)

Inserted by S.R. 2003 No. 314